Filing Analysis
Tvardi Therapeutics reported the results of its Annual Meeting of Stockholders held on June 9, 2026. Stockholders elected three Class II directors, approved executive compensation, set the frequency of compensation votes to one year, and ratified Deloitte & Touche LLP as the independent auditor.
📋 Key Facts
- Election of Class II directors: Imran Alibhai, Ph.D., Cynthia Smith, and Sujal Shah were elected to serve until the 2029 Annual Meeting.
- Executive compensation was approved on a non-binding advisory basis (3,482,265 votes For vs 161,795 Against).
- Stockholders voted for a 1-year frequency for advisory votes on executive compensation (3,453,729 votes).
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Tvardi Therapeutics, Inc. announced its financial results and business highlights for the fiscal quarter ended March 31, 2026. The disclosure was made via a press release furnished with the SEC on May 8, 2026.
📋 Key Facts
- The filing reports financial results for the first quarter of 2026.
- The press release was issued on May 8, 2026.
- The information is furnished under Item 2.02 and is not considered 'filed' for statutory liability purposes.
- The filing includes Exhibit 99.1, which contains the full text of the earnings press release.
Tvardi Therapeutics, Inc. announced its financial results and business highlights for the fiscal quarter and year ended December 31, 2025. The report was furnished under Item 2.02 and includes a press release as an exhibit.
📋 Key Facts
- The filing was made on March 31, 2026, reporting on the period ended December 31, 2025.
- The company reported under Item 2.02 (Results of Operations and Financial Condition).
- The report includes Exhibit 99.1, which is the press release detailing financial performance.
- The filing was signed by CEO Imran Alibhai.
Tvardi Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 9, 2026. The filing outlines the specific deadlines for stockholders to submit proposals and director nominations for consideration at the meeting.
📋 Key Facts
- The 2026 Annual Meeting of Stockholders is set for June 9, 2026.
- Stockholder proposals for inclusion in the proxy statement under Rule 14a-8 must be received by March 16, 2026.
- Advance notice for director nominations and other business under the Company's Bylaws must be received by March 16, 2026.
- Notice for director nominees under the SEC's universal proxy rule (Rule 14a-19) must be provided by April 10, 2026.